Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.
Seven patients with intraperitoneal pseudomyxoma originating from the appendix (4 cases) and from the ovary (3 cases) were treated with radioimmunotherapy. During the therapy, nine infusions of 3.0-4.2 GBq of 131I-labelled B72.3 monoclonal antibody were administered. We developed three-dimensional dose calculation software that can utilize activity maps based on SPET images to calculate the absorbed dose distribution using point source kernels. The dose calculation program was employed to calculate absorbed doses to various organs. The calculated dose distributions enable us to evaluate the variation in dose within the organs, which is normally not available using approaches based on geometric models. The patient-specific absorbed dose calculations were compared with doses based on a model that uses photon S-factors derived from a standard phantom. The compared doses agreed well on average, but in some organs showed large discrepancies.
Laitinen
J O
JO
Varian Medical Systems Finland Oy, Espoo, Finland. joakim.laitinen@varian.com
Tenhunen
M
M
Kairemo
K J
KJ
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000378:metabolism / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D010534:Peritoneal Neoplasms / Q000532:radiotherapy*; D011553:Pseudomyxoma Peritonei / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; C091202:B72.3 antibody; D007457:Iodine Radioisotopes